KNect365 Life Sciences is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation Therapeutics

Research Report: Cell Therapy Process Automation, Scalability and Closed Systems


Download the exclusive report

Automation and closed systems in cell therapies are some of the most exciting current developments around. Companies are implementing different types of automation to different degrees, each bringing its own set of benefits and challenges. Just how cost effective is automation today and what limitations are there to current solutions?

In November 2018 KNect365 Life Sciences conducted one of the biggest surveys of its kind across cell therapy professionals around the world. This final report based on 158 responses reveals unique insights into the level of automation today; the hottest potential opportunities; the biggest challenges and how industry insiders are tackling them.

The report also features an introduction by Dan Stanton, editor of BioProcess Insider, exploring what some of the key takeaways mean for the industry.

To download the exclusive report simply log in or register for a KNect365 account, which will give you access to all our exclusive premium content. If you are already logged in, simply hit the 'Download Now' button below.

Have any questions about the report or interested in sponsoring a future survey? Email

Automation is one of the key topics at Cell Therapy Manufacturing Asia taking place on 26 February - 1 March 2019 in Tokyo, Japan. Explore the full agenda or register for your pass.

Create your KNect365 account

Access this and more industry news, views, and keynotes from influencers and market movers.
Please tick these boxes if you do not wish to receive marketing information relevant to you from KNect365 Life Sciences:
By creating an account you agree to Informa's Terms of Use and Privacy Policy